Anne-Laure Lapeyraque, et al.: Eculizumab in Severe Shiga-Toxin-Associated HUS. In: New England Journal of Medicine. 364, 2011, S. 2561–2563, doi:10.1056/NEJMc1100859.
James F. Howard et al.: Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. In: Lancet Neurology. Band16, Nr.12, 2017, S.976–986, doi:10.1016/s1474-4422(17)30369-1, PMID 29066163.
Jun-ichi Nishimura, Masaki Yamamoto, Shin Hayashi, Kazuma Ohyashiki, Kiyoshi Ando, Andres L. Brodsky, Hideyoshi Noji, Kunio Kitamura, Tetsuya Eto, Toru Takahashi, Masayoshi Masuko, Takuro Matsumoto, Yuji Wano, Tsutomu Shichishima, Hirohiko Shibayama, Masakazu Hase, Lan Li, Krista Johnson, Alberto Lazarowski, Paul Tamburini, Johji Inazawa, Taroh Kinoshita, Yuzuru Kanakura: Genetic Variants in C5 and Poor Response to EculizumabNew England Journal of Medicine 2014, Band 370, Ausgabe 7 vom 13. Februar 2014, Seiten 632–639; doi:10.1056/NEJMoa1311084.
James F. Howard et al.: Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. In: Lancet Neurology. Band16, Nr.12, 2017, S.976–986, doi:10.1016/s1474-4422(17)30369-1, PMID 29066163.